Predict ovarian cancer by pairing serum miRNAs: Construct of single sample classifiers

• Published in: Frontiers in medicine Vol. 9; p. 923275
• Main Authors: Hong, Guini, Luo, Fengyuan, Chen, Zhihong, Ma, Liyuan, Lin, Guiyang, Wu, Tong, Li, Na, Cai, Hao, Hu, Tao, Zhong, Haijian, Guo, You, Li, Hongdong
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 02.08.2022
• Subjects: early diagnosis; Medicine; ovarian cancer; relative expression orderings; Serum miRNA; single sample classifier
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2022.923275

Objective The accuracy of CA125 or clinical examination in ovarian cancer (OVC) screening is still facing challenges. Serum miRNAs have been considered as promising biomarkers for clinical applications. Here, we propose a single sample classifier (SSC) method based on within-sample relative expression orderings (REOs) of serum miRNAs for OVC diagnosis. Methods Based on the stable REOs within 4,965 non-cancer serum samples, we developed the SSC for OVC in the training cohort (GSE106817: OVC = 200, non-cancer = 2,000) by focusing on highly reversed REOs within OVC. The best diagnosis is achieved using a combination of reversed miRNA pairs, considering the largest evaluation index and the lowest number of miRNA pairs possessed according to the voting rule. The SSC was then validated in internal data (GSE106817: OVC = 120, non-cancer = 759) and external data (GSE113486: OVC = 40, non-cancer = 100). Results The obtained 13-miRPairs classifier showed high diagnostic accuracy on distinguishing OVC from non-cancer controls in the training set (sensitivity = 98.00%, specificity = 99.60%), which was reproducible in internal data (sensitivity = 98.33%, specificity = 99.21%) and external data (sensitivity = 97.50%, specificity = 100%). Compared with the published models, it stood out in terms of correct positive predictive value (PPV) and negative predictive value (NPV) (PPV = 96.08% and NPV=95.16% in training set, and both above 99% in validation set). In addition, 13-miRPairs demonstrated a classification accuracy of over 97.5% for stage I OVC samples. By integrating other non-OVC serum samples as a control, the obtained 17-miRPairs classifier could distinguish OVC from other cancers (AUC>92% in training and validation set). Conclusion The REO-based SSCs performed well in predicting OVC (including early samples) and distinguishing OVC from other cancer types, proving that REOs of serum miRNAs represent a robust and non-invasive biomarker.